Pfizer’s elranatamab receives FDA and EMA filing acceptance

Pfizer announced that the U.S. FDA has granted Priority Review for the company’s Biologics License Application for elranatamab, an investigational B-cell maturation antigen CD3-targeted bispecific antibody, for the treatment of patients with relapsed or refractory multiple myeloma. Priority Review is intended to direct attention and resources from regulatory authorities toward drugs that, if approved, could offer significant improvements over existing options for serious conditions in order to make these drugs available to patients faster. The FDA’s decision on the application is expected in 2023. The European Medicines Agency has also accepted elranatamab’s marketing authorization application. The company is working closely with the EMA to facilitate their review and will provide updates on timing as appropriate.